Close Menu

NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Tuesday that its second quarter revenues were flat year over year, falling short of the consensus Wall Street estimate.

The Redwood City, California-based molecular diagnostics firm had total revenues of $70.6 million for the three months ended June 30, compared to $70.5 million in the second quarter of 2014. It fell short of the consensus Wall Street estimate of $71.7 million.

As in the first quarter, all of Genomic Health's revenues in the most recent quarter came from product sales.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.